domperidone has been researched along with Movement Disorders in 4 studies
Domperidone: A specific blocker of dopamine receptors. It speeds gastrointestinal peristalsis, causes prolactin release, and is used as antiemetic and tool in the study of dopaminergic mechanisms.
domperidone : 1-[3-(Piperidin-1-yl)propyl]-1,3-dihydro-2H-benzimidazol-2-one in which the 4-position of the piperidine ring is substituted by a 5-chloro-1,3-dihydro-2H-benzimidazol-2-on-1-yl group. A dopamine antagonist, it is used as an antiemetic for the short-term treatment of nausea and vomiting, and to control gastrointestinal effects of dopaminergic drugs given in the management of parkinsonism. The free base is used in oral suspensions, while the maleate salt is used in tablet preparations.
Movement Disorders: Syndromes which feature DYSKINESIAS as a cardinal manifestation of the disease process. Included in this category are degenerative, hereditary, post-infectious, medication-induced, post-inflammatory, and post-traumatic conditions.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We examined the effects of the black box warning about the risk of tardive dyskinesia (TD) with chronic use of metoclopramide on management of gastroparesis within a single clinical practice, and on reporting of adverse events." | 3.79 | The metoclopramide black box warning for tardive dyskinesia: effect on clinical practice, adverse event reporting, and prescription drug lawsuits. ( Deepak, P; Devi, R; Du, H; Ehrenpreis, ED; Leikin, JB; Sifuentes, H, 2013) |
| " Chronic administration of estradiol markedly reduced the apomorphine-induced potentiation of the dyskinesia but did not affect the tremor." | 1.27 | Biphasic effect of estradiol and domperidone on lingual dyskinesia in monkeys. ( Bédard, P; Boucher, R; Di Paolo, T; Labrie, F, 1983) |
| "Lisuride is a potent dopamine agonist and it is highly soluble in water." | 1.27 | Problems in daily motor performances in Parkinson's disease: the continuous dopaminergic stimulation. ( Agnoli, A; Brughitta, G; Ruggieri, S; Stocchi, F, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (75.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ehrenpreis, ED | 1 |
| Deepak, P | 1 |
| Sifuentes, H | 1 |
| Devi, R | 1 |
| Du, H | 1 |
| Leikin, JB | 1 |
| Bédard, P | 2 |
| Boucher, R | 2 |
| Di Paolo, T | 2 |
| Labrie, F | 2 |
| Stocchi, F | 1 |
| Ruggieri, S | 1 |
| Brughitta, G | 1 |
| Agnoli, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Pilot, Randomized, Double-blind, Placebo-controlled Trial of Promethazine for Treatment of Diabetic Gastroparesis.[NCT02130622] | Phase 2 | 3 participants (Actual) | Interventional | 2014-07-31 | Terminated (stopped due to Lack of recruitment) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 other studies available for domperidone and Movement Disorders
| Article | Year |
|---|---|
The metoclopramide black box warning for tardive dyskinesia: effect on clinical practice, adverse event reporting, and prescription drug lawsuits.
Topics: Adverse Drug Reaction Reporting Systems; Domperidone; Dopamine Antagonists; Drug Labeling; Gastropar | 2013 |
Biphasic effect of estradiol and domperidone on lingual dyskinesia in monkeys.
Topics: Animals; Apomorphine; Domperidone; Dose-Response Relationship, Drug; Estradiol; Female; Macaca fasci | 1983 |
Interaction between estradiol, prolactin, and striatal dopaminergic mechanisms.
Topics: Animals; Corpus Striatum; Domperidone; Dopamine; Estradiol; Female; Haloperidol; Macaca fascicularis | 1984 |
Problems in daily motor performances in Parkinson's disease: the continuous dopaminergic stimulation.
Topics: Administration, Oral; Adult; Aged; Carbidopa; Domperidone; Ergolines; Female; Humans; Infusions, Int | 1986 |